Introducing the Spinal Cord Neuromodulator (SCONE™)
An innovative device that treats urinary incontinence allowing people living with neurogenic bladder due to spinal cord injury, multiple sclerosis, or stroke to live their lives on their own terms. It is simple to use and results in lasting functional improvement.
SCONE™ has received FDA Breakthrough Device Designation, meaning there is no similar competitive device on the market and the proposed therapy is significantly better than the current standard of care (SoC).
Neurogenic bladder
Neurogenic bladder (NB) is a common comorbidity that people experience after paralysis, stroke or alongside MS. It has the largest impact on their quality of life. Surveys suggest that individuals living with paralysis rate improvement in bladder, bowel and sexual function as a higher priority than restoration of their ability to walk, or even resolution of chronic pain.
How it works
SCONE™ therapy is delivered through comfortable hydrogel electrode pads that are placed on the skin over specific regions of the spinal column.
Treatment protocol
- 60 minute session length
- 2 sessions per week
- 12 week program length
SCONE™ therapy results in global improvements
Reduced Urgency
Need for Fewer Catheters
Restored Sensation
Improved Capacity
Reduced Leaks
Reduced Frequency
No current SoC therapy can address all of these simultaneously.
Clinical trials
SCONE™ has been recognized by the FDA as a breakthrough device
Bringing innovation to market
At SpineX, accessibility is key to our mission. We are pushing the boundaries of research to find the most effective solutions for patients with neurological conditions and, with our devices on the market, we will have the potential to impact millions of people around the world.